Cogent Biosciences Inc (COGT)

Dec 9, 2024, 12:52 PM EST - 5 weeks ago

Why Is Cogent Biosciences Stock Trading Higher On Monday?

Dec 9, 2024, 7:00 AM EST - 5 weeks ago

Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients

Dec 8, 2024, 12:00 PM EST - 5 weeks ago

Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

Jun 14, 2024, 7:30 AM EDT - 7 months ago

Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)

May 23, 2024, 5:05 PM EDT - 8 months ago

Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer

May 23, 2024, 5:01 PM EDT - 8 months ago

Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting

May 7, 2024, 8:00 AM EDT - 9 months ago

Cogent Biosciences Reports First Quarter 2024 Financial Results

Apr 9, 2024, 9:00 AM EDT - 10 months ago

Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor

Feb 26, 2024, 8:00 AM EST - 11 months ago

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Feb 22, 2024, 2:30 PM EST - 11 months ago

Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis

Feb 14, 2024, 7:00 AM EST - 1 year ago

Cogent Biosciences Announces Oversubscribed $225 Million Private Placement

Feb 5, 2024, 9:00 AM EST - 1 year ago

Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting

Jan 9, 2024, 8:00 AM EST - 1 year ago

Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics

Jan 2, 2024, 8:00 AM EST - 1 year ago

Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 11, 2023, 8:23 AM EST - 1 year ago

Cogent Biosciences stock drops as analysts see tough competition for mastocytosis treatment

Dec 11, 2023, 7:55 AM EST - 1 year ago

Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

Dec 9, 2023, 1:30 PM EST - 1 year ago

Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

Dec 7, 2023, 9:00 AM EST - 1 year ago

Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3Kα inhibitor programs at the San Antonio Breast Cancer Symposium

Nov 29, 2023, 8:00 AM EST - 1 year ago

Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium

Nov 2, 2023, 9:00 AM EDT - 1 year ago

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results

Oct 14, 2023, 12:30 PM EDT - 1 year ago

Cogent Biosciences Presents Preclinical Data Highlighting Precision Oncology Pipeline at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Aug 15, 2023, 5:03 PM EDT - 1 year ago

Cogent Biosciences Is Beginning To Differentiate Its KIT Inhibitor

Aug 8, 2023, 8:00 AM EDT - 1 year ago

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results

Jul 7, 2023, 11:23 AM EDT - 1 year ago

3 Lost Formula Stocks to Consider for the 2nd Half of 2023

CRC IRWD

Jun 9, 2023, 4:01 PM EDT - 1 year ago

Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock

Jun 7, 2023, 9:00 AM EDT - 1 year ago

Cogent Biosciences Announces Participation in the Jefferies Healthcare Conference

Jun 6, 2023, 8:25 PM EDT - 1 year ago

Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock

Jun 6, 2023, 4:05 PM EDT - 1 year ago

Cogent Biosciences Announces Proposed Public Offering of Common Stock

Jun 3, 2023, 2:15 PM EDT - 1 year ago

Cogent Biosciences Announces Positive Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST)

May 27, 2023, 7:02 AM EDT - 1 year ago

Cogent Biosciences: APEX Part 2 Launched, ErbB2 And FGFR2 On Track

May 23, 2023, 8:00 AM EDT - 1 year ago

Cogent Biosciences to Host Investor Webcast to Discuss Lead-In Data Being Presented at ASCO from the Ongoing Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST)

May 9, 2023, 8:00 AM EDT - 1 year ago

Cogent Biosciences Reports Recent Business Highlights and First Quarter 2023 Financial Results

Apr 17, 2023, 9:00 AM EDT - 1 year ago

Cogent Biosciences Presents Preclinical Data at AACR Annual Meeting Highlighting Precision Therapy Pipeline and Announces Initiation of Part 2 of the Registration-Enabling APEX Trial with Bezuclastinib in Advanced Systemic Mastocytosis

Apr 12, 2023, 8:00 AM EDT - 1 year ago

Cogent Biosciences Announces Participation at Upcoming Investor Conferences

Mar 14, 2023, 8:00 AM EDT - 2 years ago

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results

Feb 28, 2023, 2:17 AM EST - 2 years ago

Cogent Biosciences: Bezuclastinib's Potential In Treating Gastrointestinal Stromal Tumors

Jan 9, 2023, 8:00 AM EST - 2 years ago

Cogent Biosciences Announces Planned 2023 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Cancer Therapeutics

Jan 5, 2023, 8:00 AM EST - 2 years ago

Cogent Biosciences Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference

Dec 27, 2022, 7:02 PM EST - 2 years ago

Cogent Biosciences: Multiple Inflection Points For FY23, Hold For Now

Dec 11, 2022, 5:30 PM EST - 2 years ago

Cogent Biosciences Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

Dec 5, 2022, 8:00 AM EST - 2 years ago

Cogent Biosciences to Host Investor Webcast to Discuss Updated Clinical Data at ASH from the Ongoing Phase 2 APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis

Nov 28, 2022, 4:15 PM EST - 2 years ago

Cogent Biosciences Appoints Rachael Easton, MD, Ph.D., VP, Head of Clinical Development

Nov 14, 2022, 7:00 AM EST - 2 years ago

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2022 Financial Results

Nov 3, 2022, 9:05 AM EDT - 2 years ago

Cogent Biosciences Announces Bezuclastinib Presentations at the 64th Annual American Society of Hematology (ASH) Meeting

Oct 26, 2022, 7:00 AM EDT - 2 years ago

Cogent Biosciences to Showcase Precision Therapy Pipeline at the EORTC-NCI-AACR Annual Meeting

Sep 13, 2022, 1:16 PM EDT - 2 years ago

Cogent Biosciences: What's Ahead

Aug 9, 2022, 7:00 AM EDT - 2 years ago

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2022 Financial Results

Jun 16, 2022, 4:01 PM EDT - 2 years ago

Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jun 13, 2022, 9:48 PM EDT - 2 years ago

Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock and Pre-funded Warrants